In summary, we revealed two molecular subtypes of STAD and three PANoptosis‐related signatures (APOD, GPC3, and SERPINE1), which were utilized to construct the RiskScore model with good robustness in assessing the immunotherapy response and prognostic outcomes for STAD patients. This evidence concerns the gene APOD and gastric adenocarcinoma.